AtriCure, Inc. (ATRC)
USD 30.25
(-3.97%)
USD 30.25
(-3.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -30.43 Million USD | 34.49% |
| 2022 | -46.46 Million USD | -192.56% |
| 2021 | 50.19 Million USD | 204.24% |
| 2020 | -48.15 Million USD | -36.83% |
| 2019 | -35.19 Million USD | -66.5% |
| 2018 | -21.13 Million USD | 21.4% |
| 2017 | -26.89 Million USD | 19.34% |
| 2016 | -33.33 Million USD | -22.51% |
| 2015 | -27.21 Million USD | -67.86% |
| 2014 | -16.21 Million USD | -41.43% |
| 2013 | -11.46 Million USD | -52.14% |
| 2012 | -7.53 Million USD | -38.1% |
| 2011 | -5.45 Million USD | -43.88% |
| 2010 | -3.79 Million USD | 77.01% |
| 2009 | -16.49 Million USD | -62.24% |
| 2008 | -10.16 Million USD | 9.65% |
| 2007 | -11.25 Million USD | 17.96% |
| 2006 | -13.71 Million USD | -8.16% |
| 2005 | -12.68 Million USD | -34.18% |
| 2004 | -9.45 Million USD | -32.98% |
| 2003 | -7.1 Million USD | 21.29% |
| 2002 | -9.03 Million USD | -151.14% |
| 2001 | -3.59 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -13.26 Million USD | -35.55% |
| 2024 Q2 | -8 Million USD | 39.65% |
| 2024 Q3 | -7.85 Million USD | 1.94% |
| 2023 Q1 | -6.47 Million USD | -55.3% |
| 2023 Q4 | -9.78 Million USD | -8.11% |
| 2023 FY | -30.43 Million USD | 34.49% |
| 2023 Q2 | -5.11 Million USD | 20.97% |
| 2023 Q3 | -9.05 Million USD | -76.92% |
| 2022 Q2 | -14.84 Million USD | 2.25% |
| 2022 Q3 | -12.27 Million USD | 17.31% |
| 2022 Q4 | -4.17 Million USD | 66.02% |
| 2022 FY | -46.46 Million USD | -192.56% |
| 2022 Q1 | -15.18 Million USD | -10.49% |
| 2021 Q3 | 97.1 Million USD | 697.55% |
| 2021 Q1 | -16.91 Million USD | 8.86% |
| 2021 Q2 | -16.25 Million USD | 3.94% |
| 2021 FY | 50.19 Million USD | 204.24% |
| 2021 Q4 | -13.74 Million USD | -114.15% |
| 2020 Q4 | -18.56 Million USD | -275.07% |
| 2020 FY | -48.15 Million USD | -36.83% |
| 2020 Q1 | -16.4 Million USD | -1.94% |
| 2020 Q2 | -8.23 Million USD | 49.8% |
| 2020 Q3 | -4.94 Million USD | 39.91% |
| 2019 FY | -35.19 Million USD | -66.5% |
| 2019 Q2 | -4.1 Million USD | 27.22% |
| 2019 Q3 | -9.36 Million USD | -128.29% |
| 2019 Q4 | -16.09 Million USD | -71.93% |
| 2019 Q1 | -5.63 Million USD | -64.29% |
| 2018 Q2 | -338 Thousand USD | 96.66% |
| 2018 FY | -21.13 Million USD | 21.4% |
| 2018 Q4 | -3.43 Million USD | 52.59% |
| 2018 Q3 | -7.23 Million USD | -2040.53% |
| 2018 Q1 | -10.13 Million USD | -292.79% |
| 2017 Q2 | -6.88 Million USD | 32.41% |
| 2017 Q1 | -10.18 Million USD | -18.06% |
| 2017 FY | -26.89 Million USD | 19.34% |
| 2017 Q4 | -2.58 Million USD | 64.39% |
| 2017 Q3 | -7.24 Million USD | -5.27% |
| 2016 Q3 | -6.78 Million USD | 17.34% |
| 2016 Q1 | -9.72 Million USD | 10.9% |
| 2016 FY | -33.33 Million USD | -22.51% |
| 2016 Q2 | -8.2 Million USD | 15.61% |
| 2016 Q4 | -8.62 Million USD | -27.16% |
| 2015 Q2 | -4.89 Million USD | 7.12% |
| 2015 FY | -27.21 Million USD | -67.86% |
| 2015 Q3 | -6.14 Million USD | -25.56% |
| 2015 Q4 | -10.91 Million USD | -77.72% |
| 2015 Q1 | -5.26 Million USD | 1.46% |
| 2014 Q1 | -7.7 Million USD | -54.8% |
| 2014 FY | -16.21 Million USD | -41.43% |
| 2014 Q2 | -2.69 Million USD | 65.08% |
| 2014 Q4 | -5.34 Million USD | -1046.78% |
| 2014 Q3 | -466 Thousand USD | 82.69% |
| 2013 Q2 | -1.79 Million USD | 7.82% |
| 2013 Q1 | -1.94 Million USD | 3.81% |
| 2013 Q4 | -4.98 Million USD | -81.22% |
| 2013 Q3 | -2.74 Million USD | -53.43% |
| 2013 FY | -11.46 Million USD | -52.14% |
| 2012 Q3 | -2.56 Million USD | -93.59% |
| 2012 Q4 | -2.02 Million USD | 21.31% |
| 2012 Q2 | -1.32 Million USD | 18.14% |
| 2012 FY | -7.53 Million USD | -38.1% |
| 2012 Q1 | -1.61 Million USD | 22.11% |
| 2011 Q1 | -1.27 Million USD | -11127.77% |
| 2011 Q4 | -2.07 Million USD | -79.83% |
| 2011 FY | -5.45 Million USD | -43.88% |
| 2011 Q3 | -1.15 Million USD | -22.15% |
| 2011 Q2 | -946.65 Thousand USD | 25.64% |
| 2010 Q4 | 11.54 Thousand USD | 101.12% |
| 2010 Q2 | -764.5 Thousand USD | 61.95% |
| 2010 Q3 | -1.02 Million USD | -34.64% |
| 2010 Q1 | -2 Million USD | 15.93% |
| 2010 FY | -3.79 Million USD | 77.01% |
| 2009 Q1 | -7.96 Million USD | -148.96% |
| 2009 Q4 | -2.39 Million USD | 49.12% |
| 2009 Q3 | -4.69 Million USD | -225.49% |
| 2009 Q2 | -1.44 Million USD | 81.88% |
| 2009 FY | -16.49 Million USD | -62.24% |
| 2008 Q3 | -1.76 Million USD | -11.14% |
| 2008 FY | -10.16 Million USD | 9.65% |
| 2008 Q1 | -3.6 Million USD | -130.32% |
| 2008 Q2 | -1.59 Million USD | 55.83% |
| 2008 Q4 | -3.19 Million USD | -80.75% |
| 2007 Q1 | -4.3 Million USD | -0.91% |
| 2007 FY | -11.25 Million USD | 17.96% |
| 2007 Q2 | -2.78 Million USD | 35.22% |
| 2007 Q4 | -1.56 Million USD | 39.75% |
| 2007 Q3 | -2.59 Million USD | 6.78% |
| 2006 FY | -13.71 Million USD | -8.16% |
| 2006 Q1 | -3.08 Million USD | 22.94% |
| 2006 Q2 | -3.2 Million USD | -3.84% |
| 2006 Q3 | -3.15 Million USD | 1.64% |
| 2006 Q4 | -4.26 Million USD | -35.11% |
| 2005 Q3 | -3.96 Million USD | -69.22% |
| 2005 Q4 | -4 Million USD | -1.14% |
| 2005 Q1 | -2.36 Million USD | 63.11% |
| 2005 FY | -12.68 Million USD | -34.18% |
| 2005 Q2 | -2.34 Million USD | 0.99% |
| 2004 FY | -9.45 Million USD | -32.98% |
| 2004 Q4 | -6.41 Million USD | -280.54% |
| 2004 Q2 | -197.38 Thousand USD | 0.0% |
| 2004 Q3 | -1.68 Million USD | -753.99% |
| 2003 FY | -7.1 Million USD | 21.29% |
| 2002 FY | -9.03 Million USD | -151.14% |
| 2001 FY | -3.59 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | 51.932% |
| AngioDynamics, Inc. | -184.34 Million USD | 83.489% |
| Avinger, Inc. | -18.32 Million USD | -66.146% |
| Azenta, Inc. | -14.25 Million USD | -113.495% |
| BioLife Solutions, Inc. | -66.42 Million USD | 54.178% |
| The Cooper Companies, Inc. | 294.2 Million USD | 110.346% |
| Daxor Corporation | 280.64 Thousand USD | 10945.924% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | -100.276% |
| Femasys Inc. | -14.24 Million USD | -113.643% |
| GlucoTrack, Inc. | -7.09 Million USD | -328.885% |
| Harvard Bioscience, Inc. | -3.41 Million USD | -791.303% |
| Hologic, Inc. | 789.5 Million USD | 103.855% |
| ICU Medical, Inc. | -29.65 Million USD | -2.64% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 101.693% |
| KORU Medical Systems, Inc. | -13.74 Million USD | -121.511% |
| LeMaitre Vascular, Inc. | 30.1 Million USD | 201.106% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -356.792% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -356.792% |
| Masimo Corporation | 81.5 Million USD | 137.347% |
| Microbot Medical Inc. | -10.74 Million USD | -183.408% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | 361.823% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 132.24% |
| Nephros, Inc. | -1.57 Million USD | -1832.571% |
| NovoCure Limited | -207.04 Million USD | 85.299% |
| NEXGEL, Inc. | -3.15 Million USD | -864.143% |
| NEXGEL, Inc. | -3.15 Million USD | -864.143% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | 67.899% |
| OraSure Technologies, Inc. | 53.65 Million USD | 156.729% |
| Pro-Dex, Inc. | 2.12 Million USD | 1531.03% |
| Pulse Biosciences, Inc. | -42.21 Million USD | 27.889% |
| Predictive Oncology Inc. | -13.98 Million USD | -117.664% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | -931.315% |
| QuidelOrtho Corporation | -10.1 Million USD | -201.366% |
| Repligen Corporation | 41.57 Million USD | 173.209% |
| Sanara MedTech Inc. | -4.3 Million USD | -607.335% |
| STAAR Surgical Company | 21.34 Million USD | 242.587% |
| Sharps Technology, Inc. | -9.84 Million USD | -209.278% |
| Utah Medical Products, Inc. | 16.63 Million USD | 282.976% |
| DENTSPLY SIRONA Inc. | -132 Million USD | 76.941% |
| Jin Medical International Ltd. | 2.87 Million USD | 1157.525% |